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Abstract A phase 2, open-label study in 21 patients with
non-Val30Met and non-Val122Ile hereditary transthyretin
amyloidosis showed that tafamidis (20 mg daily for
12 months) stabilized these transthyretin variants. We
assessed cardiac amyloid infiltration and cardiac abnor-
malities in this same study population. At baseline, medi-
an age was 64.3 years, 11 patients were in NYHA class II,
13 had conduction abnormalities, 14 N-terminal pro-hor-
mone brain natriuretic peptide concentrations >300 pg/ml,
and 17 interventricular septal thickness >12 mm. Mean
(SD) left ventricular ejection fraction was 60.3 % (9.96).
Patients with normal heart rate variability increased from
4/19 at baseline to 8/19 at month 12 (p<0.05). Cardiac
biomarkers remained stable. Although four patients had
increases in interventricular septal thickness ≥2 mm, the
remainder had stable septal wall thickness. There were no
clinically relevant changes in mean echocardiographic/
electrocardiographic variables and no safety concerns.
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Abbreviations
E/A Ratio of early (E) over late (atrial A) peak
diastolic mitral inflow velocity
E/e′ Ratio of early peak diastolic mitral inflow
velocity (E) over the early diastolic mitral
annular velocity (e′)
HRDB Heart rate response to deep breathing
HRV Heart rate variability
IVS Left ventricular interventricular septal
thickness
LV Left ventricular
LVEF Left ventricular ejection fraction
LVPW Left ventricular posterior wall thickness




Hereditary transthyretin (TTR) amyloidosis is a rare progres-
sive disease dominated by cardiomyopathy and/or
polyneuropathy [1, 2]. The pathophysiology of this disorder
involves a mutation in the TTR gene that destabilizes the tet-
rameric TTR protein, resulting in accelerated tetramer disso-
ciation and misfolded monomers that aggregate into insoluble
amyloid fibrils. These fibrils infiltrate the myocardium and
cardiac conduction system or peripheral and autonomic nerves
and can also build up in other organs (e.g., gastrointestinal
tract, kidneys, and eyes) [1, 2]. They disrupt normal tissue
structure and lead to progressive organ failure [1, 2]. TTR
cardiomyopathy can also occur in the absence of genetic
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mutations, often in elderly males (wild-type TTR amyloidosis
or senile systemic amyloidosis) [1, 3].
Hereditary TTR amyloidosis is a highly heterogeneous dis-
ease associated with over 100 mutations of the TTR gene [4].
Penetrance and severity of disease manifestations are highly
variable, and the typical clinical picture and course of disease
of different TTR mutations are only beginning to be defined.
Certain mutations produce a primarily neurological phenotype
(e.g., Val30Met; [5, 2]), others are associated almost exclu-
sively with cardiac problems (e.g., Val122Ile; [6]), whereas
numerous other mutations induce mixed phenotypes.
Polyneuropathy associated with TTR amyloidosis is typi-
cally characterized by small fiber, sensory-motor neuropathy
involving symptoms such as pain, sensory loss, numbness,
and motor deficits, including walking difficulties [2]. Once
such neuropathy symptoms appear, progressive autonomic
or cardiac dysfunction leads to death within an average of
10 years [2].
Cardiac manifestations in TTR amyloidosis can range from
asymptomatic arrhythmias to severe restrictive cardiomyopa-
thy with heart failure [7, 8, 1]. Cardiomyopathy is the domi-
nant clinical manifestation in patients harboring the aforemen-
tioned Val122Ile mutation or Thr60Ala, Ile68Leu, Ser77Tyr,
and Leu111Met mutations [9, 1, 3]. Patients with considerable
cardiac abnormalities tend to be older at the onset of disease
and have reduced survival rates thereafter [3].
Because TTR is produced primarily in the liver, transplan-
tation of a liver with wild-type TTR genes can be an effective
therapy, particularly in patients with Val30Met mutations, and
when performed early in the disease before extensive amyloid
deposits have accumulated [10, 11, 2]. However, liver trans-
plantation is associated with inherent risks, particularly those
accompanying chronic immunosuppression [10, 12].
Furthermore, it frequently fails to prevent the progression of
cardiomyopathy and conduction disturbances [13, 14, 12],
probably due to deposition of wild-type TTR onto pre-
existing amyloid deposits [15, 2]. This may partially explain
the reduced 5-year survival rates after liver transplantation
reported for non-Val30Met patients [16] and has led surgeons
to consider combined liver and heart transplantation in certain
cases [1].
Pharmacologic therapy of hereditary TTR amyloidosis has
become a possibility with the development of TTR stabilizers,
which target the rate-limiting step in the formation of amyloid
fibrils [17, 18]. By specifically binding to the tetramers, TTR
stabilizers increase tetramer stability and inhibit their dissoci-
ation into amyloidogenic monomers [19, 18]. One example is
diflunisal, a generic nonsteroidal anti-inflammatory drug that
was found to reduce the rate of progression of polyneuropathy
and to preserve quality of life in patients with TTR familial
amyloid polyneuropathy [20]. However, nonsteroidal anti-
inflammatory drugs can cause sodium retention and renal dys-
function, limiting or preventing the use of diflunisal in
subjects with cardiomyopathy or heart failure. Another TTR
stabilizer is tafamidis meglumine [21] that was shown in an
18-month, randomized, controlled, clinical trial to slow the
progression of peripheral neurologic impairment in patients
with TTR amyloid polyneuropathy carrying the Val30Met
mutation [22]. We recently reported on the results of a subse-
quent open-label study examining the effects of tafamidis in
patients with non-Val30Met TTR mutations [23]. This study
demonstrated that tafamidis was well tolerated and effectively
s tabi l ized te t ramer ic TTR in th is TTR amyloid
polyneuropathy patient population [23]. Furthermore, explor-
atory efficacy results indicate that the utility of tafamidis ob-
served in Val30Met patients may extend to patients with TTR
amyloidosis, regardless of the underlying TTR mutation [23,
24].
Considering that cardiac amyloidosis and electrocardio-
graphic and echocardiographic changes tend to progress de-
spite liver transplantation [13, 15, 25] and, thereby, severely
limit the benefits of this procedure in patients with cardiac
manifestations, it is of particular importance to determine
whether the observed efficacy of tafamidis on neurological
symptoms also extends to cardiac outcomes. Thus, the current
post hoc analysis examined safety and efficacy of tafamidis
with respect to cardiac structure and function in the previously
described [23] study population of non-Val30Met and non-
Val122Ile patients with TTR amyloidosis.
Methods
Patients, Study Design, and Outcomes
As described previously [23], this 12-month, open-label study
was conducted at four research centers in France, Germany,
Italy, and the USA from June 2008 to January 2010. Eligible
patients were men and non-pregnant women 18 to 75 years of
age who had symptomatic, biopsy-confirmed TTR amyloid
polyneuropathy (i.e., peripheral neuropathy or autonomic neu-
ropathy) due to a known pathogenic TTR mutation other than
the previously studied Val30Met mutation [22] or the
Val122Ile mutation assessed in a separate study (clinical trial
identifier: NCT00694161). All patients received tafamidis
20 mg (in a soft gelatin capsule) once daily.
Besides evaluating TTR stabilization, safety and tolerabil-
ity of tafamidis meglumine, and changes in neurological func-
tion, this study also examined exploratory efficacy outcomes
to assess pre-treatment cardiac involvement at baseline and
the effects of tafamidis treatment on cardiac function at month
6 and month 12. These exploratory outcomes included 12-
lead electrocardiography, 24-h Holter monitoring, heart rate
response to deep breathing (HRDB), cardiac biomarkers (N-
terminal pro-hormone brain natriuretic peptide (NT-proBNP)
and troponin I), and echocardiography. In addition to the
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standard evaluations at baseline, month 6, and month 12, elec-
trocardiography and biomarker evaluations were also per-
formed at weeks 2, week 6, and month 3. For consistency of
interpretation, electrocardiograms, echocardiograms, and 24-h
Holter monitoring results were read at a central laboratory. To
assess HRDB, the average heart rate difference was measured
while patients took a series of eight deep breaths at the optimal
rate for maximum heart rate variability (i.e., six breaths per
minute) and then compared with normative values.
Statistical Analyses
The safety and intent-to-treat populations consisted of all en-
rolled patients who received ≥1 dose of tafamidis. Analyses
were performed based on observed data from the intent-to-
treat population. For the exploratory efficacy end points, the
observed values and change from baseline over time for con-
tinuous variables as well as treatment-emergent categorical
abnormalities were summarized at each follow-up time point
by descriptive statistics.
Categorical echocardiographic abnormalities included: left
ventricular (LV) posterior or septal wall thickness >12 mm
(primary echocardiographic evidence for myocardial amy-
loidosis [26]), LV ejection fraction (LVEF) <50 %, ratio of
early (E) over late (atrial; A) peak diastolic mitral inflow ve-
locity (E/A ratio) ≥2, ratio of E over the early diastolic mitral
annular velocity (e′; E/e′ ratio) >15 (evidence of elevated LV
filling pressure), E deceleration time ≤150 ms, isovolumic
relaxation time ≤70 ms, abnormal regional wall motion valve
thickening, valvular regurgitation, right ventricular thickness
≥7 mm, abnormal respiratory variation of inferior vena cava
(evidence of elevated right ventricular filling pressure), and
pericardial effusion.
Treatment-emergent Holter monitoring abnormalities includ-
ed atrial fibrillation/flutter, atrial tachycardia, non-sustained ven-
tricular tachycardia (<30 beats), sustained ventricular tachycar-
dia (≥30 beats), sinus pause, and heart rate variability (HRV).
HRVindices included the percentage of successive RR intervals
with >50 ms difference between beats (pNN50), the root mean
square of successive differences of the RR intervals (ms) be-
tween normal beats (RMS-SD), theMagid standard deviation of
all RR intervals (ms) for all 5-min segments, and the Kleiger
standard deviation of all RR intervals.
We undertook post hoc analyses to evaluate changes from
baseline to month 12 in echocardiographic measures of myo-
cardial amyloid infiltration, LV systolic dysfunction, and LV
diastolic dysfunction. To assess cardiac amyloid infiltration
during tafamidis treatment, we used the International Society
of Amyloidosis’ evaluation criterion for immunoglobulin light-
chain amyloidosis that defines disease progression as increases
in IVS ≥2 mm compared with baseline [26]. Furthermore, in
the absence of a direct comparator group, we decided to use a
10 % change approach for assessing changes in LV mass
during the treatment period, with a ≥10 % increase classified
as progressive amyloid infiltration, any change <10 % as sta-
bilized disease, and a ≥10 % decrease as regression. Similarly,
using LVEF as an estimate of systolic function, we classified a
≥10 % increase in LVEF as an improvement, a ≥10 % decrease
as a deterioration, and any change <10 % as preserved func-
tional capacity. Finally, to gain some insight into changes in
diastolic function and filling pressure during tafamidis treat-
ment, all patients with evaluable assessments were categorized
into one of three groups based on their lateral E/e′ ratio (a
parameter known to be correlated to left ventricle filling pres-
sure): groupA if E/e′ <8 (low filling pressure), group B if E/e′ is
between 8 and 15, and group C if E/e′ >15 (high filling pres-
sure). This standard categorization [27] was performed at base-
line, month 6, and month 12.
Results
Patient Disposition and Baseline Characteristics
A total of 21 patients were enrolled and received ≥1 dose of
tafamidis. Two patients who were over 75 years of age but
met all other eligibility criteria were granted waivers and en-
rolled in the study.
Baseline demographic and clinical characteristics of the
study population have been reported previously [23] and
included significant neurologic deficits and impaired
disease-specific quality of life (Table 1). Looking at TTR
amyloidosis-related medical history events, all patients re-
ported symptoms of peripheral or autonomic neuropathy at
study entry. In addition, 13/21 patients (61.9 %) also report-
ed symptoms attributable to cardiomyopathy prior to their
enrollment. At baseline, 10/21 patients (47.6 %) were in
New York Heart Association class I and 11 (52.4 %) in class
II, and four patients (19.0 %) had cardiac pacemakers prior
to enrollment.
Safety Findings
Tafamidis was well tolerated. Eighteen (85.7 %) patients
completed the study and three (14.3 %) discontinued early,
one because of a transient ischemic attack and two to under-
go liver transplant. No life-threatening adverse events or
patient deaths were reported. Of the eight (38.1 %) patients
reporting serious treatment-emergent adverse events, five
experienced falls and three experienced one serious cardio-
vascular adverse event each (one coronary artery stenosis,
one transient ischemic attack, and one atrioventricular
block). The patient with the transient ischemic attack with-
drew from the study (Thr60Ala, history of hypertension);
the other two were treated by implantation of a new stent at a
site of in-stent restenosis or of a pacemaker/cardioverter-
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defibrillator respectively and recovered without any change
in study drug.
Electrographic analysis of heart rate and HRV parameters
demonstrated no adverse effects of tafamidis treatment on
cardiac conduction or repolarization; only one patient had a
change to >500 ms in QTcB (corrected QT interval calculated
using Bazett’s heart rate correction formula), and no patient
developed an increase ≥60 ms in QTcF (corrected QT interval
calculated using Fridericia’s correction method) while receiv-
ing tafamidis.
Electrocardiographic Findings
Mean heart rate and mean electrocardiography intervals were
within normal ranges at baseline. The mean (SD) QRS was
slightly prolonged at 101.8 (21.4)ms but below the abnormal
value of 120 ms. No relevant changes were observed over the
12-month study period in mean electrocardiographic measure-
ments (Table 2).
At baseline, 16/21 patients (76.2 %) had electrocardio-
graphic abnormalities (Table 3) [23]. Most frequent were con-
duction abnormalities (13/21, 61.9 % of patients) such as left
anterior hemiblock and first-degree atrioventricular block
[23]. During the 12-month study period, 9/21 patients
(42.9 %) developed new-onset, treatment-emergent electro-
cardiographic abnormalities; these were predominantly ar-
rhythmias (8/18, 44.4 %). However, the proportion of patients
with electrocardiographic abnormalities at month 12 (13/18,
72.2 %) did not exceed that at baseline.
Holter Monitoring Findings
At baseline, heart rate assessments were normal (mean [SD]
maximum heart rate, 110.9 [15.2]bpm; mean 24-h heart rate,
74.7 [12.1]bpm; minimum heart rate, 55.1 [10.7]bpm), and
there were no clinically relevant changes in these parameters
during the study period.
Holter monitoring abnormalities were seen in 14/21 pa-
tients (66.7 %) at baseline; most common were atrial tachy-
cardia (11/21, 52.4%) and non-sustained ventricular tachycar-
dia (8/21, 38.1 %) (Table 2). New, treatment-emergent abnor-
malities on Holter monitoring were seen in 9/19 patients
(47.4 %); most common were atrial tachycardia and non-
sustained ventricular tachycardia (4/21, 19 % each).
Regarding HRVassessments at baseline, mean Kleiger and
Magid standard deviation values were abnormal (≤100 ms),
but RMS-SD and pNN50 were within normal range (≥30 ms
and ≥10 %, respectively) (Fig. 1). Mean values for the HRV
indices did not deteriorate over the study period, and the num-
ber of patients with normal HRV (defined as normal pNN50,
RMS-SD, and Kleiger SD) in the safety population increased
from 4/19 (21 %) at baseline to 8/19 (42 %) at month 12 (p=
0.0455; Fig. 2).











































NIS Neuropathy Impairment Score, Norfolk QOL-DN Norfolk Quality of
Life Diabetic Neuropathy, SD standard deviation,Σ5 NCS nds Summated
Five Nerve Conduction Study normal deviate
a Neuropathy Impairment Score (NIS), a neurological assessment of mus-
cle weakness, sensory loss, and muscle reflexes; higher scores indicate
greater neurological deficit [33]
b The Summated Five Nerve Conduction Study normal deviate (Σ5 NCS
nds) composite score, an assessment of large nerve fiber function; higher
scores indicate greater neurological deficit [34]
c Here, the 35-item version of the Norfolk Quality of Life Diabetic Neu-
ropathy patient-completed questionnaire was use;, higher scores indicate
worse QOL [35]
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Heart Rate Response to Deep Breathing
HRDB is a non-invasive measure of autonomic function and
vagal cardiac response. The mean normal deviate for HRDB
in the population of patients with evaluable assessments was –
0.7 at baseline and remained stable over time (change from
baseline at month 12=–0.1) (Table 4). However, only 12/21
patients had an evaluable assessment at baseline, and of these,
only 7 also had an evaluable assessment at month 12.
Cardiac Biomarkers
The mean NT-proBNP concentration was elevated at baseline,
and no clinically relevant changes were noted during the study
[23]. There were 14 patients (66.7 %) with an NT-proBNP
concentration >300 pg/ml at baseline, 10 of whom had con-
centrations >1000 pg/ml. However, with the exception of one
patient whose NT-proBNP concentration steadily increased
from 2603 pg/ml at baseline to 7902 pg/ml at month 12, there
were no consistent clinically meaningful increases above each
individual’s baseline concentration during the 12-month
tafamidis treatment (Fig. 3).
As previously reported, mean troponin I concentrations
were within normal ranges (≤0.1 ng/ml) at baseline and
remained stable during tafamidis treatment [23]. Only one
patient had abnormal troponin I levels at baseline (0.134 ng/ml
at baseline and 0.117 ng/ml at month 12), two patients devel-
oped abnormal levels during the study (one had <0.050 ng/ml
at baseline and 0.130 ng/ml at months 6 and 12, the other had
<0.050 ng/ml from baseline to month 6 and <0.150 ng/ml at
month 12), and another study completer had one abnormal
reading at week 6 (0.110 ng/ml).
Echocardiographic Findings
Several echocardiographic measures were abnormal at base-
line including the mean (SD) values for LV posterior wall
thickness (LVPW) of 14.6 (2.6)mm [23], interventricular sep-
tal thickness (IVS) of 15.2 (2.8)mm [23], isovolumetric relax-
ation time of 84.1 (17.5) ms, and E/e′ lateral ratio of 13.1 (7.8).
Despite this evidence of cardiac amyloidosis at baseline, av-
erage echocardiographic values remained stable during the
12-month study period [23].
As previously described [23], all patients had at least one pre-
specified echocardiographic abnormality at baseline. The most
frequent echocardiographic aberrations were increased LVPW
and increased IVS (17/19, 89.5 % each) closely followed by
valve thickening (16/19, 84.2 %). In addition, 8 of 14 patients
(57.1%) had evidence of an elevated LV filling pressure, 5 of 16
patients (31.3 %) reported elevated right ventricular filling pres-
sures, and 3 of 21 patients (14.3 %) had an ejection fraction
<50 % (Table 5). During the 12-month study period, new-
onset echocardiographic abnormalities were reported in 12 of
19 patients (63.2 %), the most common being LVPW >12 mm
(2/3, 66.7%), valvular thickening (3/5, 60%), and thickening of
the right ventricular wall to ≥7 mm (6/13, 46.2 %).
At baseline, 17 of 19 patients with an evaluable assessment
(89.5 %) had left ventricular wall thickening with IVS and
LVPW of >12 mm, demonstrating amyloid infiltration of the
myocardium. At the end of the study, left ventricular wall
thickness measures remained below >12 mm threshold in
the two patients with normal IVS at baseline. As previously
reported [23], 4 of the 12 patients (33.3 %) with evidence of
cardiac amyloid at baseline and a valid assessment at month
12 demonstrated ≥2 mm increases in IVS thickness (range, 2–
6 mm), indicative of modest disease progression during the
12-month treatment period. Moreover, of the 14 patients with
available measurements, six (42.9 %) had a ≥10 % increase in
LV mass at month 12 whereas LV mass was stable in seven
(50.0 %) and decreased by >10 % from 228 to 201 g in the
14th patient (Fig. 4).
Using LVEF to estimate LV systolic function, apart from
temporary decreases in LVEF to 42 and 37 % in two patients











Heart rate, bpm n=21 n=19 n=18
Mean±SD 70.3±11.8 −0.6±10.3 −2.0±9.0
Median 71.0 −2.0 −1.5
Range 45, 95 −17, 28 −19, 12
PR interval, ms n=18 n=16 n=15
Mean±SD 182.2±36.6 5.6±15.2 5.5±17.6
Median 174.5 3.0 3.0
Range 122, 263 −14, 33 −29, 40
QRS interval, ms n=21 n=19 n=18
Mean±SD 101.8±21.4 –0.6±9.5 1.8±7.7
Median 90.0 0.0 0.5
Range 80, 139 −19, 21 −15, 17
QT interval, ms n=21 n=19 n=18
Mean±SD 411.9±50.7 6.7±20.8 6.7±34.9
Median 407.0 7.0 13.0
Range 339, 552 −26, 50 −59, 89
QTc-B, ms n=21 n=19 n=18
Mean±SD 441.1±37.2 6.6±18.9 1.4±16.6
Median 450.0 6.0 –2.0
Range 375, 507 −25, 57 −30, 42
QTc-F, ms n=21 n=19 n=18
Mean±SD 430.8±38.3 6.7±13.7 3.3±20.0
Median 435.0 7.0 3.0
Range 371, 502 −17, 32 −28, 46
bpm beat per minute, QTc-B corrected QT interval calculated using
Bazett’s heart rate correction formula, QTc-F corrected QT interval cal-
culated using Fridericia’s correction method, SD standard deviation
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at month 6, none of the 17 patients with an LVEF of ≥50 % at
baseline developed LV systolic dysfunction (LVEF <50 %)
during the 12-month tafamidis treatment. Furthermore, a post
hoc analysis showed that LVEF deteriorated by ≥10 % in two
(11.1 %) of the 18 study completers, but was maintained (n=
14, 77.8 %) or increased (n=2, 11.1 %) at the end of the 12-
month study in the others.
At baseline, left ventricular filling pressure, determined
from the lateral E/e′ ratio, was within the normal range in
6/16 (37.5 %) patients with available data, but was undeter-
mined in 5/16 (31.3 %) and elevated in another 5/16 (31.3 %)
patients. This distribution did not change markedly during
tafamidis treatment, with a small shift from normal to
undetermined.
Discussion
Previously reported findings from this open-label phase 2
study showed that tafamidis 20 mg once daily was well toler-
ated over 12 months in patients with non-Val30Met and non-
Val122Ile TTR amyloidosis with some worsening in neuro-
logical manifestations and maintenance of health-related qual-
ity of life and nutritional status [23]. This analysis extends
these results by showing that, overall, there was no clinically
meaningful deterioration in LV thickness (cardiac amyloid
infiltration), LV systolic and diastolic function, and conduc-
tion during the 12-month tafamidis treatment period. Taken
together, with findings from an earlier study in patients with
TTR amyloidosis and Val30Met mutation, the current study
provides evidence for the overall and cardiac safety of
tafamidis 20 mg once daily as a disease-modifying therapy
for patients with hereditary TTR amyloidosis, regardless of
genotype.
HRV Indices and Conductive Disorders
Electrocardiographic and Holter monitoring results and HRV
indices indicated cardiac autonomic dysfunction in most pa-
tients at baseline. Notably, mean echocardiographic, electro-
cardiographic, and Holter monitoring parameters did not show
clinically meaningful changes over the 12-month treatment
period [23]. Furthermore, the incidence of treatment-
emergent abnormalities was low to moderate, and the pattern
of observed abnormalities was comparable with that at base-
line and consistent with underlying cardiac morbidity.
Intriguingly, the number of patients with normal HRV mea-
sures increased over the 12-month treatment period. It will be
of interest to investigate whether the normalization in HRV
indices is reproducible or if it was purely due to chance, and to
prospectively test the hypothesis that tafamidis, which was
designed to slow or halt disease progression by preventing
Table 3 Electrocardiographic and Holter monitoring conductive and rhythmic abnormalities in the intent-to-treat population
Variable, n/N (%)a Pre-treatmentb Month 6 Month 12
Electrocardiography (ECG)
Any ECG abnormality 16/21 (76.2 %) 14/19 (73.7 %) 13/18 (72.2 %)
Rhythmc 3/21 (14.3 %) 9/19 (47.4 %) 6/18 (33.3 %)
Conductiond 13/21 (61.9 %) 11/19 (57.9 %) 9/18 (50.0 %)
Morphologye 1/21 (4.8 %) 1/19 (5.3 %) 1/18 (5.6 %)
Pathological Q waves 3/21 (14.3 %) 3/19 (15.8 %) 2/18 (11.1 %)
Abnormal T wave 3/21 (14.3 %) 1/19 (5.3 %) 2/18 (11.1 %)
Holter monitoring
Any holter abnormality 14/21 (66.7 %) 14/17 (82.4 %) 13/18 (72.2 %)
Atrial fibrillation/flutter 1/21 (4.8 %) 2/16 (12.5 %) 2/17 (11.8 %)
Atrial tachycardia 11/21 (52.4 %) 12/17 (70.6 %) 12/18 (66.7 %)
Non-sustained ventricular tachycardia (<30 beats) 8/21 (38.1 %) 4/17 (23.5 %) 3/18 (16.7 %)
Sustained ventricular tachycardia (≥30 beats) 0/21 (0 %) 0/17 (0 %) 0/18 (0 %)
Sinus pause 1/21 (4.8 %) 2/17 (11.8 %) 0/18 (0.0 %)
aNumber of patients with abnormality/Number of patients eligible for assessment (%) at visit
b Pre-treatment indicates that patients had ≥1 pre-treatment abnormality (at screen 1 [days −30 to −1] or baseline [day 0])
c Includes sinus pauses, sinus bradycardia, sinus tachycardia, atrial flutter, atrial fibrillation, junctional tachycardia, junctional rhythm, artificial pace-
maker, ventricular fibrillation, idioventricular rhythm, supraventricular tachycardia, ectopic supraventricular rhythm, and other arrhythmia or rhythm
disturbances
d Includes first-degree AV block, AV Mobitz I, AV Mobitz II, complete heart block, Wolff-Parkinson-White, intraventricular conduction defect, left
bundle branch block, right bundle branch block, incomplete right bundle branch block, incomplete left bundle branch block, prolonged QTc, left anterior
hemiblock, left posterior hemiblock, and other conduction abnormalities
e Includes right atrial abnormality, left atrial abnormality, right ventricular hypertrophy, left ventricular hypertrophy, low voltage, and other morpholog-
ical abnormalities
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de novo amyloid deposition, may be able to improve existing
cardiac autonomic dysfunction.
Cardiac Infiltration and LV Function
Echocardiographic abnormalities were seen in all patients
at baseline and are consistent with the presence of cardiac
amyloid deposits and restrictive/hypertrophic cardiomy-
opathy. With the exception of four patients with an in-
crease in IVS thickness ≥2 mm, no change in LV wall
thickness occurred during 12 months of tafamidis treat-
ment, suggesting that TTR amyloid deposition did not
progress in the majority of patients. This is an important
point as liver transplantation is known to fail to prevent
(or, in certain cases, has been reported to accelerate) pro-
gressive cardiac TTR amyloid deposition when cardiac
Fig. 1 Holter monitoring HRV values in the safety population showed
that mean and median values for the percentage of successive RR
intervals with >50 mg difference between normal beats (pNN50) (a),
the root mean square of successive differences of the RR intervals
between normal beats (RMS-SD) (b), the Magid SD (c), and the
Kleiger SD of all RR intervals (d) did not deteriorate over the study
period. Bars indicate the range of values observed, boxes span from the
25th to the 75th percentiles, horizontal lines within the boxes indicate
median change, and plus sign indicates mean changes. HRV heart rate
variability, SD standard deviation
Fig. 2 The proportion of patients with normal HRV in the safety
population increased from 4/19 at baseline to 8/19 at month 12
(p<0.05). p values are based on two-sided McNemar’s tests. HRV heart
rate variability, ns non-significant
Table 4 RR interval variability (normal deviates) in response to deep
breathing









Mean±SD −0.7±2.2 0.0±2.3 −0.1±1.4
Median −0.7 0.1 0.0
Range −3.7, 3.7 −2.9, 3.6 −2.0, 2.0
95 % CI −2.1, 0.7 −2.4, 2.4 −1.3, 1.2
CI confidence interval, HRDB heart rate response to deep breathing, RR
interval between two consecutive R waves in the electrocardiogram, SD
standard deviation
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hypertrophy exists before surgery [25, 28, 13]. LV filling
pressure estimated by echocardiography also remained
stable during the study.
NT-proBNP is a sensitive indicator of increased intraven-
tricular pressures in congestive heart failure and has prognos-




concentrations <300 pg/ml (a) or
>300 pg/ml (b). No consistent,
clinically meaningful increases in
NT-proBNP were detected during
12 months of tafamidis treatment,
with the exception of a steady rise
from 2603 to 7902 pg/ml in
patient 10. NT-proBNP N-
terminal pro-hormone brain
natriuretic peptide. a Patients had
missing baseline data, and the last
pre-treatment assessment during
screening is depicted. b Patient
discontinued tafamidis on day 31
following a transient ischemic
attack. c Patient discontinued
tafamidis prior to month 12 to
undergo combined liver/heart
transplant. d Patient discontinued
tafamidis prior to month 3 to
undergo a liver transplant
Table 5 Incidence of echocardiographic abnormalities in the intent-to-treat population
Parametera Baseline (N=21) Month 6 (N=19) Month 12 (N=18)
Any echocardiographic abnormality 21/21 (100.0 %) 14/18 (77.8 %) 15/18 (83.3 %)
LVEF <50 % 3/21 (14.3 %) 3/18 (16.7 %) 0/18 (0.0 %)
IVRT ≤70 ms 1/10 (10.0 %) 0/6 (0.0 %) 2/12 (16.7 %)
E/A ratio ≥2 3/18 (16.7 %) 3/14 (21.4 %) 2/17 (11.8 %)
E/e′ lateral >15 5/16 (31.3 %) 3/12 (25.0 %) 3/11 (27.3 %)
LVPW >12 mm 17/19 (89.5 %) 13/16 (81.3 %) 12/14 (85.7 %)
IVS >12 mm 17/19 (89.5 %) 13/16 (81.3 %) 12/14 (85.7 %)
Valvular thickening 16/19 (84.2 %) 13/17 (76.5 %) 10/16 (62.5 %)
Valvular regurgitation 9/19 (47.4 %) 9/17 (52.9 %) 7/14 (50.0 %)
Right ventricular thickness ≥7 mm 4/17 (23.5 %) 4/8 (50.0 %) 6/13 (46.2 %)
Inferior vena cava respiratory variation 5/18 (27.8 %) 3/12 (25.0 %) 2/15 (13.3 %)
Pericardial effusion 1/21 (4.8 %) 1/18 (5.6 %) 1/17 (5.9 %)
E/A ratio ratio of peak mitral early diastolic and atrial contraction velocity, E/e′ ratio ratio of peak mitral inflow velocity of early filling (E) and early
diastolic mitral annular velocity (e′), IVRT isovolumetric relaxation time, IVS left ventricular interventricular septal thickness, LV left ventricular; LVEF
left ventricular ejection fraction, LVPW left ventricular posterior wall thickness
a Number of patients with abnormality/number of patients eligible for assessment (%) at visit
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a growing body of evidence suggests that NT-proBNP is a
good marker for cardiac impairment (LV function and cardiac
hypertrophy) in patients with hereditary TTR amyloidosis [30,
31]. In the current analysis, NT-proBNP concentrations were
markedly elevated at baseline, yet no further meaningful
increases were reported in the vast majority of participants
reported during the course of tafamidis treatment.
In contrast with NT-proBNP, troponin I levels were normal
in all but one patient at baseline. This finding is in agreement
with a previous report that NT-proBNP is a more sensitive
marker for cardiomyopathy in TTR amyloidosis patients than
troponin I [30]. However, a recent study in patients with the
acquired form of TTR amyloidosis suggests that troponin I
may be of greater prognostic value than NT-proBNP [32].
Taken together, elevated NT-proBNP concentrations and
measures of LV thickness indicate that the current study
population had significant cardiac abnormalities at baseline.
The findings that only four patients had mild increases in LV
wall thickness and that the majority of participants had no
meaningful increase in NT-proBNP over time suggest that
cardiac disease may have been stable over the 12-month
period of tafamidis treatment. Disease progression rates in
TTR cardiac amyloidosis are not well defined, and clinical
features are known to be highly heterogeneous across TTR
mutations. Although the limited data available suggests that
a significant deterioration may be observed in LV wall
thickness, LV mass, and NT-proBNP levels during a 12-
month period [33, 34] without a matched negative control
group, it is unknown whether these measures would have
worsened in the current study population in the absence of
tafamidis treatment. Consequently, the absence of relevant
cardiac disease progression in this small sample may or may
not relate to tafamidis. However, the descriptive safety, tol-
erability, and outcome results are encouraging and justify
the further evaluation of this TTR stabilizer for the treat-
ment of TTR cardiac amyloidosis.
The hypothesis that tafamidis may slow the progression of
TTR cardiomyopathy in patients with hereditary non-V30M
transthyretin amyloidosis now needs to be confirmed in a
larger patient cohort. To this end, a 30-month, multicenter,
phase 3, double-blind, placebo-controlled, randomized trial
aiming to evaluate the efficacy, safety, and tolerability of
tafamidis in approximately 400 subjects diagnosed with
transthyretin cardiomyopathy is ongoing (clinical trial identi-
fier: NCT01994889). The prospect of a disease-modifying
therapy that may effectively ameliorate cardiac problems as-
sociated with transthyretin amyloidosis may encourage the
inclusion this often overlooked condition in the differential
diagnosis in patients with heart failure. Furthermore, we hope
that our attempts to define disease progression criteria to as-
sess whether cardiac amyloid infiltration and cardiac dysfunc-
tion progressed during tafamidis treatment will stimulate ad-
ditional research to test and validate these and other suitable
response criteria (e.g., stabilization of amyloid deposition
assessed using histologic or magnetic resonance imaging tech-
niques) for reliable measurement of the impact of tafamidis
and other investigational agents on transthyretin cardiac
amyloidosis.
Fig. 4 Changes in cardiac amyloid infiltration, systolic function, and LV
filling pressure from baseline within individual patients. a LV mass, as a
measure of cardiac amyloid infiltration, was maintained or improved
(<10 % increase) in 8/14 (57.1 %) from baseline to month 12. b LVEF
as a measure of systolic function was maintained or improved (<10 %
decrease) in 16/18 (88.9 %) from baseline to month 12. c Lateral E/e′ as
an estimate of LV filling pressure was normal (E/e′ <8), undetermined
(8≤E/e′≤15), or elevated (E/e′>15) in 6/16 (37.5 %), 5/16 (31.3 %), and
5/16 (31.3 %) at baseline and in 3/11 (27.3 %), 5/11 (45.5 %), and 3/11
(27.3 %) at month 12, respectively. LV left ventricular, LVEF LVejection
fraction, E/e′ ratio of peak mitral inflow velocity of early filling to early
diastolic mitral annular velocity
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Study Limitations
This study had limitations common to those studies involving
rare diseases, including the low number of study subjects and
the lack of a comparator patient group. The ensuing inability
to apply statistical tests to analyze the data is a major limitation
of this small, hypothesis-generating study. In addition, this
study was of relatively short duration, with an open-label de-
sign, and some of the analyses described here were post hoc.
Nevertheless, our findings are notable in demonstrating that
tafamidis seemed to cause no harm in this population of pa-
tients with non-Val30Met and non-Val122Ile TTR amyloid-
osis, most of whom had electrocardiographic or echocardio-
graphic abnormalities at baseline and that there was little pro-
gression of amyloid cardiomyopathy during the year-long
course of treatment.
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